Research community previously filed under “Oncology”

Clinical Trials for Advanced Solid Tumors: Immunotherapy, Targeted Agents, and Platinum Chemotherapy

Mostly in the field Transition Metal Chemistry, Anticancer Therapy, and Catalysis (58% of its papers), one of 4 communities there

Papers 47,837
Elements 2
Keywords & sectors 50
Leading venue Journal of Clinical Oncology

Clinical Trials for Advanced Solid Tumors: Immunotherapy, Targeted Agents, and Platinum Chemotherapy

This community focuses on the clinical evaluation of treatment regimens for advanced solid tumors, specifically testing the efficacy and safety of immunotherapies, targeted drugs, and platinum-based chemotherapy in patients with lung, ovarian, bladder, and head and neck cancers.

The research is dominated by phase III clinical trials assessing combination therapies. Recurring treatments include immune checkpoint inhibitors (such as pembrolizumab and nivolumab), antibody-drug conjugates, and targeted agents like osimertinib, often administered alongside or in place of platinum-based chemotherapy (cisplatin or carboplatin). The primary cancer types studied are non-small cell lung cancer, epithelial ovarian cancer, urothelial (bladder) carcinoma, and squamous cell carcinoma of the head and neck. The literature frequently addresses locally advanced or metastatic disease, with a strong emphasis on neoadjuvant settings and the management of platinum-resistant or recurrent cases.

Platinum research accounts for the largest share of this community's output, representing 11.3% of all tracked platinum research and comprising 18,211 papers within this group. This element leads on both the proportion of its total research and the raw paper count within the community.

The community comprises 47,837 papers, with the highest publication volume in the Journal of Clinical Oncology, Frontiers in Oncology, and Cancers.

Recent work continues to focus on perioperative immunotherapy for bladder and lung cancer, the use of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer, and updated treatment guidelines for gastric and ovarian malignancies.

Recurring themes in the literature

Phrases that recur across this community's paper titles -- a quick map of its sub-topics, drawn straight from the titles themselves.

  • lung cancer 2471
  • ovarian cancer 2156
  • cell lung 1547
  • cell carcinoma 1373
  • squamous cell 1185
  • non-small cell 940
  • head neck 888
  • locally advanced 868
  • breast cancer 804
  • targeted therapy 787
  • bladder cancer 630
  • small cell 627
  • case report 596
  • urothelial carcinoma 577
  • cancer patients 559
  • cervical cancer 544
  • gastric cancer 457
  • phase trial 436
  • platinum-based chemotherapy 401
  • immune checkpoint 399
  • cancer cells 398
  • patients advanced 360
  • neck cancer 343
  • neck squamous 332

Papers behind this description

Most cited
Signal Transduction and Targeted Therapy · 2024 · 599 citations
New England Journal of Medicine · 2024 · 567 citations
Nature Reviews Disease Primers · 2024 · 525 citations
Signal Transduction and Targeted Therapy · 2023 · 831 citations
JAMA · 2025 · 308 citations
Newest
New England Journal of Medicine · 2026 · 113 citations
New England Journal of Medicine · 2025 · 98 citations
New England Journal of Medicine · 2025 · 77 citations
Gastric Cancer · 2026 · 62 citations
The Lancet · 2026 · 42 citations

A sample from the 18 papers behind this description. Create a free account to see them all.